E–091–2019: Methods of Producing T Cell Populations Using Induced Pluripotent Stem Cells

1. US Provisional Patent Application 62/957,939 filed January 7, 2020 (E–091–2019–0–US–01).

*Group C*

E–174–2012: Methods of Producing T Memory Stem Cell Populations

1. International Patent Application PCT/US2012/053947 filed September 6, 2012 (E–174–2012–0–PCT–01);
2. United States Patent 10,316,289 issued June 11, 2019 (E–174–2012–0–US–02.; and
3. United States Patent Application 16/410,327 filed May 13, 2019 (E–174–2012–0–US–03).

The patent rights in these inventions have been assigned and/or exclusively licensed to the government of the United States of America.

The prospective exclusive license territory may be worldwide, and the fields of use may be limited to the following:

Field of Use Applying to Intellectual Property Group A

''Manufacture and commercialization of companion diagnostics approved or cleared by the FDA or equivalent foreign regulatory agency for Licensee-proprietary T cell therapy products.''

Field of Use Applying to Intellectual Property Group B

''Manufacture and commercialization of adoptive T cell therapy products generated from autologously-derived, induced pluripotent stem cells for the treatment of cancer in humans.''

Field of Use Applying to Intellectual Property Group C

''Manufacture and commercialization of adoptive T cell therapy products isolated from peripheral blood for the treatment of cancer in humans.''

E–022–2017 generally discloses methods of using certain gene signature profiles to identify cancer patients likely to respond to T cell immunotherapy.

E–250–2016 generally discloses in vitro methodologies for generating induced pluripotent stem cell-based thymic emigrants and methods of using the same for the treatment of cancer.

E–132–2017 generally discloses methods of generating multi-potent hematopoietic progenitor cells from induced pluripotent stem cells and methods of using the same for the treatment of cancer.

E–133–2017 generally discloses methods of generating autologous thymic organoids from human pluripotent stem cells and methods of treating cancer using T cells produced by such organoids.

E–091–2019 generally discloses methods of reprogramming tumor infiltrating lymphocytes into induced pluripotent stem cells and methods of treating cancer using such cells.

E–174–2012 generally discloses a method of generating stem cell-like memory T cells by stimulating naive T cells in the presence of GSK–3beta inhibitors, and methods of treating cancer using cells conditioned in such a manner.

This Notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive license will be royalty bearing, and the prospective exclusive license may be granted unless within fifteen (15) days from the date of this published Notice, the National Cancer Institute receives written evidence and argument which establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.

In response to this Notice, the public may file comments or objections. Comments and objections, other than those in the form of a license application, will not be treated confidentially, and may be made publicly available.

License applications submitted in response to this Notice will be presumed to contain business confidential information and any release of information from these license applications will be made only as required and upon a request under the Freedom of Information Act, 5 U.S.C. 552.

Dated: March 23, 2020.

**Richard U. Rodriguez,**

*Associate Director, Technology Transfer Center, National Cancer Institute.*

[FR Doc. 2020–06922 Filed 4–1–20; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

### National Cancer Institute; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the joint meeting of the National Cancer Advisory Board and NCI Board of Scientific Advisors.

The meeting will be held as a virtual meeting and is open to the public. Individuals who plan to view the virtual meeting and need special assistance or other reasonable accommodations to view the meeting, should notify the Contact Person listed below in advance of the meeting.

A portion of the National Cancer Advisory Board meeting will be closed to the public in accordance with the provisions set forth in section 552b(c)(6), Title 5 U.S.C., as amended, for the review, discussion, and evaluation of individual intramural programs and projects conducted by the National Cancer Institute, including consideration of personnel qualifications and performance, and the competence of individual investigators, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Cancer Advisory Board and NCI Board of Scientific Advisors.

*Date:* April 9, 2020.

*Open:* 1:00 p.m. to 3:15 p.m.

*Agenda:* Joint meeting of the National Cancer Advisory Board and NCI Board of Scientific Advisors, NCI Director's report and other related business.

*Closed:* 3:15 p.m. to 4:00 p.m.

*Agenda:* Review of ongoing intramural research efforts and the discussion of confidential personnel issues.

*Place:* National Cancer Institute Shady Grove, 9609 Medical Center Drive, Rockville, MD 20850 (Virtual Meeting).

Instructions regarding access to the meeting can be found here:

NCAB: *https://deainfo.nci.nih.gov/advisory/ncab/ncabmeetings.htm*

BSA: *https://deainfo.nci.nih.gov/advisory/bsa/bsameetings.htm*

*Contact Person:* Paulette S. Gray, Ph.D., Executive Secretary, Division of Extramural Activities, National Cancer Institute—Shady Grove, National Institutes of Health, 9609 Medical Center Drive, 7th Floor, Room 7W444, Bethesda, MD 20892, 240–276–6340, *grayp@mail.nih.gov.*

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Information is also available on the Institute's/Center's home page:

NCAB: *https://deainfo.nci.nih.gov/advisory/ncab/ncabmeetings.htm,*

BSA: *https://deainfo.nci.nih.gov/advisory/bsa/bsameetings.htm,* where an agenda, instructions for access, and any additional information for the meeting will be posted when available.

This notice is being published less than 15 days prior to the meeting due to scheduling difficulties.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and

Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: March 29, 2020.

**Melanie J. Pantoja,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2020–06871 Filed 4–1–20; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

### Prospective Grant of an Exclusive Patent License: The Development of Bispecific Antibodies Targeting Glypican 1 (GPC1) for the Treatment of GPC1-Expressing Human Cancer

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this notice to NeoImmune Tech, Inc. (NeoImmune), located in Rockville, Maryland.

**DATES:** Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before April 17, 2020 will be considered.

**ADDRESSES:** Requests for copies of the patent application, inquiries, and comments relating to the contemplated an Exclusive Patent License should be directed to: David Lambertson, Ph.D., Senior Technology Transfer Manager, NCI Technology Transfer Center, 9609 Medical Center Drive, RM 3W610 MSC 9702, Bethesda, MD 20892–9702 (for business mail), Rockville, MD 20850–9702 Telephone: (240)-276–6467; Email: *david.lambertson@nih.gov.*

**SUPPLEMENTARY INFORMATION:**

**Intellectual Property**

U.S. Provisional Patent Application 62/795,415 entitled ''High Affinity Monoclonal Antibodies Targeting Glypican-1 For Treating Pancreatic Cancer'' [HHS Ref. E–028–2019–0–US–01], PCT Patent Application PCT/US2020/013739 entitled ''High Affinity Monoclonal Antibodies Targeting Glypican-1 For Treating Pancreatic Cancer'' [HHS Ref. E–028–2019–0–PCT–02], and U.S. and foreign patent applications claiming priority to the aforementioned applications.

The patent rights in these inventions have been assigned and/or exclusively licensed to the government of the United States of America.

The prospective exclusive license territory may be worldwide and the field of use may be limited to:

The research, development and commercialization of a bispecific antibody having the following elements:

(A) a first antibody component that binds to glypican 1 (GPC1), comprised of:

(1) an antibody having the complementary determining region (CDR) sequences of the antibody known as HM2, or

(2) an antibody having the CDR sequences of the antibody known as D4; and

(B) a second antibody component that binds to CD3;

For the treatment of GPC1-expressing human cancers.

The Licensed Field of Use specifically excludes any unconjugated mono-specific therapeutic antibodies and non-specified immunoconjugates, including, but not limited to, chimeric antigen receptors (CARs) and variants thereof, recombinant immunotoxins, and antibody-drug conjugates (ADCs).

This technology discloses antibodies that are specific for the cell surface domain of GPC1. GPC1 is a protein that is aberrantly expressed on several forms of cancer, including pancreatic cancer. The antibodies can be used either as unconjugated agents, or in the form of immunoconjugates (such as bispecific antibodies, CARs, ADCs and immunotoxins) to specifically target diseased cells that express GPC1, These agents can be used for the selective destruction of the diseased cells, resulting in treatment that may not have severe deleterious effects seen with less specific therapeutic modalities.

This notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive license will be royalty bearing, and the prospective exclusive license may be granted unless within fifteen (15) days from the date of this published notice, the National Cancer Institute receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.

In response to this Notice, the public may file comments or objections. Comments and objections, other than those in the form of a license application, will not be treated confidentially, and may be made publicly available.

License applications submitted in response to this Notice will be presumed to contain business confidential information and any release of information in these license applications will be made only as required and upon a request under the Freedom of Information Act, 5 U.S.C. 552.

Dated: March 24, 2020.

**Richard U. Rodriguez,**

*Associate Director, Technology Transfer Center, National Cancer Institute.*

[FR Doc. 2020–06917 Filed 4–1–20; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

### National Institute on Alcohol Abuse and Alcoholism; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Clinical, Treatment and Health Services Research Review Subcommittee, June 19, 2020, 8:30 a.m. to June 19, 2020, 5:00 p.m., JW Marriott New Orleans, 3rd Floor, Suite 1, 614 Canal Street, New Orleans, LA 70130 which was published in the **Federal Register** on March 18, 2020, 85 FR 15485.

This notice is being amended to change the meeting location from the JW Marriott New Orleans, 3rd Floor, Suite 1, 614 Canal Street, New Orleans, LA 70130 to a telephone conference call. The meeting is closed to the public.

Dated: March 30, 2020.

**Melanie J. Pantoja,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2020–06920 Filed 4–1–20; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HOMELAND SECURITY

### Coast Guard

**[Docket No. USCG–2020–0048]**

### National Offshore Safety Advisory Committee; April 2020 Teleconference

**AGENCY:** U.S. Coast Guard, Department of Homeland Security.

**ACTION:** Notice of Federal Advisory Committee teleconference meeting.

**SUMMARY:** The National Offshore Safety Advisory Committee (Committee) will